EP
GMAB icon

Essential Partners’s Genmab GMAB Stock Holding History

Essential Partners’s Portfolio GMAB Stock Details GMAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.21K Hold
226
– – ﹤0.01% 1442
2026
Q1 		$6.06K Sell
226
-53
-19% -$1.59K ﹤0.01% 1491
2025
Q4 		$8.59K Hold
279
– – ﹤0.01% 1214
2025
Q3 		$8.56K Buy
+279
New +$6.8K ﹤0.01% 1219

Other funds holding GMAB

PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Essential Partners's GMAB Position: Q2 2026 in Review

Essential Partners held its Genmab (GMAB) position steady in Q2 2026 at 226 shares worth $6.21K. The position accounts for ﹤0.01% of the portfolio, ranked #1442.

Essential Partners first reported a position in GMAB in Q3 2025 and has held it in 4 quarters since. The position peaked at $8.59K in Q4 2025. 291 funds tracked by Wall St. Rank hold GMAB as of Q2 2026.

  • Essential Partners held 226 shares of Genmab worth $6.21K as of Q2 2026.
  • Essential Partners left its Genmab share count unchanged in Q2 2026.
  • Genmab made up ﹤0.01% of Essential Partners's portfolio in Q2 2026, its #1442 holding.
  • Essential Partners first reported a position in Genmab in Q3 2025 and has held it in 4 quarters since.
  • Essential Partners's Genmab position peaked at $8.59K in Q4 2025.
  • 291 funds tracked by Wall St. Rank held Genmab as of Q2 2026.

Based on Essential Partners's 13F filing for Q2 2026, filed 10 Aug 2026.